ometinib

Ometinib is a drug name that does not appear in standard pharmaceutical databases or the provided clinical context. Based on the context provided, which focuses on Akebia Therapeutics and Janssen Pharmaceutica's collaboration on hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors, it is possible that the name is a misspelling or an obscure reference. The primary compounds discussed in the context are vadadustat (an oral HIF-PH inhibitor for anemia) and JNJ5169 (a preclinical HIF-PH inhibitor for inflammatory bowel disease). Without further specific data identifying ometinib as a distinct chemical entity or a recognized synonym for an existing drug, its pharmacological profile remains uncharacterized.